Northern Light Venture Capital has led a $25-million series B financing in a clinical stage company TenNor Therapeutics, according to the company’s statement.
Existing investors Frontline BioVentures, WuXi Pharma Tech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund also joined this round.
The company said that the proceeds will be used to advance new antibiotics into the late-stage of clinical development.
TenNor possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development, while it keeps developing new drugs for other diseases continuously.
“With the infusion of the new capital, TenNor is well positioned to deliver the best treatment for H. pylori and other GI tract infections to patients in the coming years,” said TenNor’s founder and chief executive Dr. Zhenkun Ma.
TenNor Therapeutics was established in 2013 in BioBAY, a life science park based in Suzhou, China. It has acquired patents and other assets from Cumbre IP Venture and patents from the TB Alliance.
Northern Light Venture Capital is a China-focused venture capital firm targeting early stage opportunities of innovation and disruptive technology. Since its inception in 2005, Northern Light has backed over 180 ventures in TMT, healthcare and advanced technology.